The role of interleukin-2 during homeostasis and activation of the immune system.
about
The environment of regulatory T cell biology: cytokines, metabolites, and the microbiomeThe 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responsesBreaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical CancerAntigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 DiabetesRegulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in TransplantationInsights into cytokine-receptor interactions from cytokine engineeringIL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetesIL-2 sensitivity and exogenous IL-2 concentration gradient tune the productive contact duration of CD8(+) T cell-APC: a multiscale modeling studyRemote control of therapeutic T cells through a small molecule-gated chimeric receptor.Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cellsThe Immune System of HIV-Exposed Uninfected InfantsIL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?Emerging Therapies for Rheumatoid ArthritisDiacylglycerol Kinases in T Cell Tolerance and Effector FunctionThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyOxalate upregulates expression of IL-2Rβ and activates IL-2R signaling in HK-2 cells, a line of human renal epithelial cellsAnti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous LeukemiaRegulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialApplication of the adverse outcome pathway (AOP) concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food proteinsThe effects of interleukin-2 on immune response regulation.Alarmin IL-33 elicits potent TB-specific cell-mediated responses.The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells.CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.Restoring the balance: immunotherapeutic combinations for autoimmune diseaseReactive oxygen species are required for driving efficient and sustained aerobic glycolysis during CD4+ T cell activation.Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosisCytokine Receptor Endocytosis: New Kinase Activity-Dependent and -Independent Roles of PI3K.A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsFc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapySexual Dimorphic Responses in Lymphocytes of Healthy Individuals after Carica papaya Consumption.Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responsesClonal Expansion of Allergen-specific CD4+ T Cell in the Lung in the Absence of Lymph NodesMicroRNA Regulation in Systemic Lupus Erythematosus PathogenesisConstrained release of lamina-associated enhancers and genes from the nuclear envelope during T-cell activation facilitates their association in chromosome compartments.Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.IAP antagonists induce anti-tumor immunity in multiple myeloma.
P2860
Q21131158-E2A23613-7E27-4344-8EFA-10937AB8DE0FQ24616434-1EEDEABC-C694-4C7F-83C2-90D22BBF173FQ26744624-51E64D06-40A4-4DBC-B223-EA0C081A97A4Q26747008-B3FB6D14-AB9E-44D9-8A18-61DD603A59B0Q26770386-C9F30CE2-006D-46F1-AC6F-6915357D2E50Q26784460-F2A4E58E-240A-4853-B2AB-4B21E7F559DCQ26852703-2B036C7E-EF81-435E-AF9D-B732D29C8F09Q27303126-21A152E8-73DC-4D92-BAF0-9261113CBD00Q27304738-9313CA82-B89F-4155-A961-41296D4F3E8CQ27330599-1F6D6F14-DEA2-4A81-BEEF-693BF73DC281Q28068375-B4CDF038-3C8D-414A-A7BA-D21FB0D3B3A5Q28069872-693D501C-E73B-44C4-AA28-192DFD9D77B3Q28073154-52CB3F5D-214F-43A2-9233-2F15B478E8E8Q28078943-8644D0FE-B21F-4101-90F9-2FD063C8FC98Q28079616-0C2562B6-E41E-47FD-8449-CCCE4FDAE33FQ28088784-9A8B4CF4-D928-46DE-8E26-56FB4A080F93Q28538519-8349B6AA-D126-4F88-A21E-FCE8728DB958Q28552291-83FDD1D0-CEDB-41B2-80DF-E7BDC3279B33Q28554636-79511F9B-2127-4350-AB35-28690CDA12A3Q29994477-3380046B-5446-44CB-A991-791460229162Q30252875-3159AA54-E64A-48DA-9584-D2C477484539Q30375869-AEA9E937-DA17-4B3B-B1F9-6B85F5BD3FACQ30388273-4C2B762B-7300-49A3-93A6-46CBF12081F3Q30426856-E466D792-09D8-4E3A-ABC4-6DE407E1E612Q33555986-7A6490AE-AD5D-4889-A59F-3C397A365074Q33584702-32BE5B57-76E7-4F5D-9F16-4C7C9788EC9EQ33589947-49A52BA7-0340-43B2-990F-BD825E3C1536Q33619529-7EDC2673-836A-41A0-873F-D2993A5E6E7BQ33626683-1CF36DAF-75E4-45B0-BE96-690F7C789C24Q33636478-63FC0460-54EF-4201-8A23-1C7F528823DBQ33705698-339C657C-834B-4596-99FF-0DA1982FAB16Q33707098-D4ACFFC9-DDB8-4DC7-AC47-F5206D07F4CBQ33730033-3991CC0B-E453-47D2-B563-683CC4923103Q33780598-87990D1A-6404-40F7-9E6B-ABB94086F37AQ33816125-9B338F39-0EAA-42CE-8D99-D9A6A33EE8CDQ33835108-85AABABF-AF51-4D1B-9BCA-5E1D3991531AQ33838816-1A7EFCB3-14AF-4A9C-B290-E0DE8E700B01Q33865147-00B413FE-095D-46D5-B303-5C7B2D1AB8E8Q33873731-ADB4CBBE-F901-4A54-AC31-9D0788813109Q33914862-18FBF57D-E608-471F-8C04-49BC070E0047
P2860
The role of interleukin-2 during homeostasis and activation of the immune system.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The role of interleukin-2 during homeostasis and activation of the immune system.
@ast
The role of interleukin-2 during homeostasis and activation of the immune system.
@en
The role of interleukin-2 during homeostasis and activation of the immune system.
@nl
type
label
The role of interleukin-2 during homeostasis and activation of the immune system.
@ast
The role of interleukin-2 during homeostasis and activation of the immune system.
@en
The role of interleukin-2 during homeostasis and activation of the immune system.
@nl
prefLabel
The role of interleukin-2 during homeostasis and activation of the immune system.
@ast
The role of interleukin-2 during homeostasis and activation of the immune system.
@en
The role of interleukin-2 during homeostasis and activation of the immune system.
@nl
P356
P1476
The role of interleukin-2 during homeostasis and activation of the immune system.
@en
P304
P356
10.1038/NRI3156
P577
2012-02-17T00:00:00Z